Pharmacokinetics of Atazanavir in Special Populations

CompletedOBSERVATIONAL
Enrollment

32

Participants

Timeline

Start Date

September 2, 2019

Primary Completion Date

May 1, 2020

Study Completion Date

November 30, 2022

Conditions
HIV/AIDSTuberculosis
Interventions
DRUG

Atazanavir 300mg/ Ritonavir 100 mg once daily

There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care

DRUG

Atazanavir 250 mg / ritonavir 80 mg

There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care. This dose of 250/ 80 is for participants weighing between 15 and 25 Kg

Trial Locations (4)

Unknown

Desmond Tutu HIV Foundation, Cape Town

University of Cape Town, Cape Town

Infectious Diseases Institute, Kampala

Joint Clinical Research Centre, Kampala

All Listed Sponsors
collaborator

Makerere University

OTHER

collaborator

Joint Clinical Research Centre- Kampala

UNKNOWN

collaborator

Desmond Tutu HIV Foundation

OTHER

collaborator

University of Cape Town

OTHER

collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP) - funder

UNKNOWN

lead

University of Liverpool

OTHER